Skip to content

ConMed

US · CNMD #3018 by market cap Listed 1970
46.56 +0.18 +0.39%
Periodic snapshot; not a real-time feed. · 2026-11-20 19:30

Valuation each multiple against its own 5-year range

P/B ratio 1.42 Cheap vs history 20th percentile
5-year average 2.98 · #44 of 127 in Medical Devices
P/E ratio 20.99 In line with history 49th percentile
5-year average 19.26 · forward 12.55 · #15 of 39 in Medical Devices
P/S ratio 1.10 Cheap vs history 21st percentile
5-year average 2.13 · forward 1.07 · #36 of 136 in Medical Devices

Vs. peers Medical Devices

Company Market cap P/E (TTM) P/B Div yield
ConMed (CNMD) 1.39B 19.32 1.31 0.00%
Abbott Laboratories (ABT) 178.39B 38.29 3.50 2.41%
Medtronic (MDT) 127.84B 24.62 2.54 2.85%
Stryker Corp (SYK) 118.01B 33.01 5.03 1.14%
Boston Scientific (BSX) 60.85B 17.71 2.37 0.00%
Edwards Lifesciences (EW) 58.56B 57.54 5.39 0.00%

Other StockVane-tracked companies in the same industry.

Morningstar

★★★★☆ Fair value62.14 Economic moatNone UncertaintyMedium

Trading 33.5% below Morningstar's fair value estimate.

Fair value

Conmed Corp earns a 4-star quantitative star rating, illustrating our stance that this share class offers a somewhat attractive opportunity for investors. The stock currently trades at a 19% discount to our quantitative fair value estimate of $62.14 per share; however, some caution is warranted due to this estimate's medium uncertainty rating.

The firm's profitability strengthens our estimated fair value. Highly profitable companies are often more resilient in recessions and are likely to generate stronger future cash flows for shareholders. Reflecting the firm's profitability is its earnings yield of 9.2%, which sits in the top 30% globally. This suggests that it is generating substantial earnings relative to its share price, which contributes to our view that shares are cheap.

The company's valuation metrics are an additional encouraging factor. A company's valuation metrics provide insights into the market's expectations for its future growth and profitability. The firm's book value yield of 68.9%, a core component of valuation, sits in the top 45% compared with global peers. The market price is low relative to the book (accounting) value of the company's equity, which further promotes our favorable price/fair value ratio.

Economic moat

This company lacks a competitive advantage, receiving a quantitative economic moat rating of none. Additionally, the firm's moderate financial health score suggests it is acceptably positioned against adverse economic circumstances.

By Quantitative Equity Report

Quote time 2026-11-20 19:30:06 · For reference only, not investment advice and not tailored to your situation.

ConMed discussion 0 comments

Add a comment